Roberto Ezequiel Borgia1, Earl D Silverman. 1. Division of Rheumatology, Hospital for Sick Children, Hospital for Sick Children Research Institute, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: This is an update of the main studies published in the last year regarding biomarkers, advances in pathophysiology, lupus nephritis as well as outcomes and therapies in childhood-onset systemic lupus erythematosus (cSLE). RECENT FINDINGS: Some progress in the pathophysiology of cSLE was made in the past year. Although biomarkers were studied in lupus nephritis and neuropsychiatric lupus, none of the proposed biomarkers was shown to be a significant improvement over current disease measures. More encouraging was the research into creating an easy, rapid screening tool for neurocognitive dysfunction in cSLE. Two studies in health-related quality of life (HRQL) recognized its importance in determining outcome and found that ethnicity and obesity might significantly alter HRQL in cSLE patients. There were no prospective clinical trials involving cSLE patients. SUMMARY: A better understanding of pathophysiology may elucidate novel molecules as therapeutic targets in cSLE. Advances in the field of biomarkers may enable a more accurate prediction of clinical outcome, optimizing early interventions and therefore improving disease prognostics.
PURPOSE OF REVIEW: This is an update of the main studies published in the last year regarding biomarkers, advances in pathophysiology, lupus nephritis as well as outcomes and therapies in childhood-onset systemic lupus erythematosus (cSLE). RECENT FINDINGS: Some progress in the pathophysiology of cSLE was made in the past year. Although biomarkers were studied in lupus nephritis and neuropsychiatric lupus, none of the proposed biomarkers was shown to be a significant improvement over current disease measures. More encouraging was the research into creating an easy, rapid screening tool for neurocognitive dysfunction in cSLE. Two studies in health-related quality of life (HRQL) recognized its importance in determining outcome and found that ethnicity and obesity might significantly alter HRQL in cSLE patients. There were no prospective clinical trials involving cSLE patients. SUMMARY: A better understanding of pathophysiology may elucidate novel molecules as therapeutic targets in cSLE. Advances in the field of biomarkers may enable a more accurate prediction of clinical outcome, optimizing early interventions and therefore improving disease prognostics.
Authors: Samar A Soliman; Anam Haque; Sherene Mason; Larry A Greenbaum; M John Hicks; Chandra Mohan; Scott E Wenderfer Journal: Lupus Date: 2021-05-14 Impact factor: 2.911
Authors: Ellen M Cody; James E Rose; Bin Huang; Tingting Qiu; Hermine I Brunner; Prasad Devarajan Journal: Front Pediatr Date: 2022-07-29 Impact factor: 3.569
Authors: Ellen M Cody; Michael R Bennett; Gaurav Gulati; Qing Ma; Mekibib Altaye; Prasad Devarajan; Hermine I Brunner Journal: Kidney Int Rep Date: 2021-04-28
Authors: Sulaiman M Al-Mayouf; Rehab Fallatah; Mohammed Al-Twajery; Tareq Alayed; Abdullah Alsonbul Journal: Int J Pediatr Adolesc Med Date: 2019-07-09